• Cold agglutinin disease revisited: a multinational, observational study of 232 patients 

      Berentsen, Sigbjørn; Barcellini, Wilma; D'Sa, Shirley; Randen, Ulla; Tvedt, Tor Henrik Anderson; Fattizzo, Bruno; Haukås, Einar; Kell, Megan; Brudevold, Robert; Dahm, Anders Erik Astrup; Dalgaard, Jakob; Frøen, Hege; Hallstensen, Randi; Jæger, Pernille Horgmo; Hjorth-Hansen, Henrik; Malecka, Agnieszka Maria; Oksman, Markku; Rolke, Jürgen; Sekhar, Mallika; Sørbø, Jon Hjalmar; Tjønnfjord, Eirik; Tsykunova, Galina; Tjønnfjord, Geir Erland (Peer reviewed; Journal article, 2020)
      We retrospectively studied 232 patients with cold agglutinin disease (CAD) at 24 centers in 5 countries. In Norway and a northern region of Italy, the study was close to being population-based. For the first time, we ...
    • Long-term outcomes of patients treated with rituximab as second-line treatment for adult immune thrombocytopenia – Follow-up of the RITP study 

      Tjønnfjord, Eirik; Holme, Pål Andre; Darne, Bernadette; Khelif, Abderrahim; Waage, Anders; Michel, Marc; Romdhan, Neila Ben; Ghanima, Waleed Khalid (Peer reviewed; Journal article, 2020)
      RITP was a double‐blind randomized, 78‐week follow‐up trial in which 109 adults with immune thrombocytopenias (ITP) who failed to achieve adequate response to steroids, were randomized to receive rituximab or placebo. Here, ...